Item 2.02 Results of Operations and Financial Condition.

Gritstone bio, Inc. (the "Company") estimates that its cash, cash equivalents, marketable securities and restricted cash as of December 31, 2021 was approximately $223.5 million. The Company's actual consolidated cash, cash equivalents, marketable securities and restricted cash balance as of December 31, 2021 may differ from these estimates due to the completion of the Company's year-end closing and auditing procedures.

Spokespersons of Gritstone will be presenting the information provided in this item 2.02 of this Form 8-K at various upcoming meetings beginning January 10, 2022.

The information provided in this Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses